Pramipexole Shows Promise as Add-On Therapy for Treatment-Resistant Depression
A new study published in *Nature Medicine* suggests that pramipexole, a medication typically used to treat Parkinson’s disease, may offer relief for patients with treatment-resistant depression characterized by anhedonia, or the inability to feel pleasure. The findings, led by researchers at Lund University and Region Skåne in Sweden, highlight the potential of drug repurposing in addressing mental health challenges.
How Does Pramipexole Work for Anhedonia?
Pramipexole, a dopamine agonist, targets the brain’s reward system by stimulating dopamine receptors. This mechanism is believed to address the neural underpinnings of anhedonia, a core symptom of depression that current antidepressants often fail to alleviate. “Anhedonia is one of the most debilitating aspects of depression, and our results suggest pramipexole could be a breakthrough for this patient group,” said Daniel Lindqvist, a researcher at Lund University and senior consultant in psychiatry.
Study Design and Results
The randomized, placebo-controlled trial involved 120 participants with treatment-resistant depression and marked anhedonia. Over nine weeks, patients received either pramipexole or a placebo alongside their existing antidepressant regimen. Those taking pramipexole showed significantly greater improvements in mood and motivation, with effects persisting during a six-month follow-up. Brain imaging (7 Tesla fMRI) revealed enhanced activity in the ventral striatum, a region linked to reward processing.
Side Effects and Safety
Most participants tolerated pramipexole well, with common side effects including sleep disturbances, nausea, and dizziness. These were managed by dose adjustments. Long-term follow-up data indicated sustained efficacy and safety, though researchers caution against potential risks like impulse control issues and daytime fatigue. “Monitoring for side effects is critical, especially in long-term treatment,” noted Marie Asp, a psychiatric researcher at Lund University.
Implications for Depression Treatment
The study underscores the growing trend of drug repurposing in psychiatry. By leveraging existing medications, researchers can accelerate the development of new therapies. “This approach could reduce the time and cost associated with traditional drug discovery,” said Filip Ventorp, a postdoctoral researcher involved in the study. The findings also align with broader efforts to target dopamine pathways in mood disorders.
What’s Next for Patients?
While the results are promising, larger trials are needed to confirm pramipexole’s efficacy and safety in diverse populations. Clinicians emphasize that it should not replace standard antidepressants but serve as an adjunct for specific cases. “This is a significant step forward, but more research is required before it becomes a standard option,” Lindqvist added.